Speaker: Evangelos Terpos

0:28:53

Evangelos Terpos, Professor of Hematology, University of Athens, Greece

0:02:45

Myeloma: real-world data

0:02:22

A novel prognostic system based on circulating tumor cells for newly diagnosed multiple myeloma

0:01:30

Message to Myeloma patients in Greek

0:01:22

Phase II study of isatuximab, pomalidomide and dexamethasone in lenalidomide-exposed R/R myeloma

0:03:25

Advice for managing bone disease in multiple myeloma

0:03:07

Comparing continuous and fixed duration myeloma treatment with triplets and doublets

0:03:30

The evolving imaging of multiple myeloma

0:00:57

Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment

0:03:38

Denosumab: the next big drug in myeloma?

0:03:34

The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma

0:01:16

Deciphering the association between ocular AEs and the clinical activity of belamaf in myeloma

0:33:23

Multiple Myeloma in Underserved Populations (Episode 1)

0:03:03

The prognostic impact of circulating plasma cells in patients with multiple myeloma

0:01:25

Real world data: bortezomib-based therapy for R/R myeloma

0:03:31

Myeloma: Optimizing treatment

0:03:09

Real world data for len/dex in second-line myeloma: what does this tell us?

0:04:01

The pros and cons of MRI and PET-CT for assessing response in multiple myeloma

0:01:40

Open questions in the use of imaging techniques for assessing response in multiple myeloma

0:46:42

Latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma

0:02:38

DARIA: daratumumab with ixazomib and dexamethasone for R/R myeloma

0:03:39

Novel agents for myeloma related bone disease

0:02:23

The safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment

0:00:45

Key findings of the Endeavour study